Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus CHILDREN S MOTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus CHILDREN S MOTRIN.
BUTAZOLIDIN vs CHILDREN'S MOTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
None Documented
None Documented
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
2-4 hours in children; prolonged in neonates and hepatic impairment.
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Category C
Category C
NSAID
NSAID